VRTX vs. REGN, SNY, GSK, BMY, ZTS, PFE, TAK, ABT, RPRX, and BGNE
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Sanofi (SNY), GSK (GSK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Abbott Laboratories (ABT), Royalty Pharma (RPRX), and BeiGene (BGNE). These companies are all part of the "pharmaceutical preparations" industry.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Regeneron Pharmaceuticals presently has a consensus target price of $989.36, suggesting a potential upside of 0.72%. Vertex Pharmaceuticals has a consensus target price of $432.18, suggesting a potential downside of 2.93%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Regeneron Pharmaceuticals had 15 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 30 mentions for Regeneron Pharmaceuticals and 15 mentions for Vertex Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.97 beat Vertex Pharmaceuticals' score of 0.64 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Vertex Pharmaceuticals received 61 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.63% of users gave Vertex Pharmaceuticals an outperform vote while only 66.59% of users gave Regeneron Pharmaceuticals an outperform vote.
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Regeneron Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Vertex Pharmaceuticals' net margin of 29.45%. Regeneron Pharmaceuticals' return on equity of 23.08% beat Vertex Pharmaceuticals' return on equity.
Summary
Regeneron Pharmaceuticals and Vertex Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
